Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 18/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 18/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL70546 | 0.98 | HTR2C (0.54) | HTR2CSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL92138 | 0.78 | NOS3 (0.36) | HTR2CSLC6A2SLC6A4 | |
| SCHEMBL83792 | 0.77 | SLC6A4 (0.47) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL70403 | 0.77 | SLC6A2 (0.38) | HTR2CSLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL70914 | 0.75 | HTR2C (0.38) | HTR2CSLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL70661 | 0.75 | SLC6A4 (0.46) | HTR2CSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1006288 | 0.74 | SIGMAR1 (0.45) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5183725 | 0.74 | RBP4 (0.48) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3174299 | 0.73 | TAS1R3 (0.38) | HTR2CSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL7331996 | 0.73 | SIGMAR1 (0.44) | HTR2CSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129376-B2 | Piperidine derivatives as inhibitors of stearoyl-CoA desaturase | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-03-06 | — | — | US | disclosed |
| US-7951805-B2 | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase | XENON PHARMACEUTICALS INC. (CA) | 2011-05-31 | — | — | US | disclosed |
| CN-102036558-A | Novel piperidine derivatives as stearoyl-CoA desaturase inhibitors | FOREST LAB HOLDINGS LTD | 2011-04-27 | — | — | CN | disclosed |
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2009-09-24 | — | — | US | disclosed |
| US-20070299081-A1 | Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa Desaturase | XENON PHARMACEUTICALS INC. (CA) | 2007-12-27 | — | — | US | disclosed |
| EP-1799668-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDIATORS OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006034338-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDIATORS OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239810-A1 | NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE | SCD, SCD5, FADS2 | HTR2C 3384/4885SLC6A2 4356/4885SLC6A4 4287/4885 |
| US-20070299081-A1 | Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa Desaturase | SCD, SCD5, NR1H2 | HTR2C 3104/4885SLC6A2 4724/4885SLC6A4 4725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.